Brenda is based in Christchurch, and is originally from Auckland. Brenda is known in NZ as a top mortgage adviser and has been on the NZ Top Advisers list for a number of years now. Mike Sweeney leads Talent and Partnership Activation at Vega Group, driving strategic initiatives to attract, develop, and retain top talent. She is responsible for implementing marketing projects, internal and external marketing initiatives. Results from PPC campaigns are measurable and targetable in very specific niches, unlike the advertise-the-benefits approach that classical marketing channels adopt. For more info in regards to marketing service take a look at our own web site. Each page should be optimised for the specific geographic location and include relevant local keywords, client testimonials, and contact information. Brenda started her working life at BNZ where she spent 10 years before moving to be a mortgage advisor looking after her own client base. Brenda has a husband and two young children, and you’ll find them at the ski fields in the winter and at beaches during the summer!
bbc.co.ukAt the highest level of the judicial system is the UK Supreme Court, which has jurisdiction over constitutional issues, human rights cases, and appeals of significant legal importance. The administration of the Supreme Court includes ensuring the smooth operation of the appeal process. Given the importance of the Supreme Court in shaping UK law, its administrative team is highly specialized to manage the volume and complexity of the cases it handles.
SRC:MixSentence, IDs:4F45A2FE;8E020393;430C4AF5;D7418648;029700BB;3AD5669B;CEC0943E;5E804A06;2C342F27;6B520626;EA73E075;F7F7F036;167CCA31;FEE5A7E4;AF24C528;07405E10;FDCAA27E;F1FE3AF6;F4EC029B;CC2BCDF5;49E5C53D;CE505E59;A29C6F39;103B5D06;878FED22;63624C40;03D22A85
"The time it takes for a new technology to be adopted by 50 percent of US households has long been used by economic historians for cross-technology comparisons. We would like to help draft this manuscript," Marcia Zabusky, a vice president of Intramed, told the doctors in a conference call, according to a transcript of the conversation obtained by The New York Times, "and then submit it to you for your - for your editing and for approval." During the call, Shane Schaffer, a Novartis marketing executive, told the doctors that the company wanted "a quick, down and dirty" article. A study expected to provide scientific data showing Ritalin LA's advantages was not scheduled to start until the following day, he said, but the lack of research findings should not be an obstacle. "Obviously, we have to stick within data limits of what's published currently as well as what we know are factual about these products," he told the doctors. "But, of course, inferences can be made." One such "potential theoretical conclusion" of the article, Ms. Zabusky added, was that a drug that worked for 9 hours might be better than a 12-hour drug. The doctors - John S. Markowitz and Kennerly S. Patrick of the Medical University of South Carolina - agreed to what Intramed and Novartis proposed. "I think we're quite clear on what you want the next manuscript to look like," Dr. Patrick said as the call concluded. To produce the new draft, Intramed turned to Linda Logdberg, who has a doctorate in anatomy and has made her living the last 12 years as a ghostwriter for Intramed and other medical marketing companies. Starting with an outline approved by Intramed, Dr. Logdberg said that she produced a new manuscript in a few days. The assignment was one of her last ghostwriting tasks. Dr. Logdberg, who recently took a job teaching biology to high school students, said that she had become increasingly disenchanted with the process. Typically, she said, her manuscript would be sent to the drug company for approval before it was given to the doctors who were paid to be listed as the authors. Some doctors fretted over each comma, Dr. Logdberg said, while others made no changes at all. The marketing companies, she added, "will drop a doctor if they don't think he will be particularly malleable." The result, Dr. Logdberg said, is marketing masquerading as science. "What I mind is advertising that calls itself education." The ad agencies' medical education companies say that they neither toy with science nor ghostwrite articles that physicians use to make decisions about prescribing drugs. "We make editorial suggestions," said Jed A. Beitler, chairman of Sudler & Hennessey, a division at WPP that includes Intramed. "The doctors are the ultimate writers." Dr. Markowitz and Dr. Patrick agreed, saying that Intramed did not dictate what their paper should say. "No figure, no table, anything goes in without our approval," Dr. Markowitz said. Dr. Patrick added that he thought, based on past research, that a drug like Ritalin LA could be better for certain children than other long-lasting drugs. Neither the doctors nor the companies disputed the accuracy of the transcript of their conference call. Novartis said the free article was not intended to conclude that one product was better than the others. Instead, the company said, it was a review of the available medications in which the authors could suggest theoretical advantages. Mr. Beitler said that Intramed was unhappy with the manuscript that Dr. Logdberg produced and later gave the assignment to another writer. The article has not been published. A 1998 survey of named authors writing for some of the nation's top journals, including The Journal of the American Medical Association, which published the survey, found that 11 percent of the articles had been ghostwritten. Some experts think the practice continues to grow, even as the best journals take steps to prevent it. Wyeth hired ghostwriters in promoting the diet drug combination fen-phen, according to documents made public in litigation filed after it became evident that fen-phen caused a potentially deadly heart-valve defect. Evidence of ghostwriting has also surfaced in federal and state investigations of Warner-Lambert's marketing of Neurontin, an epilepsy drug, for more than a dozen unapproved uses. One document made public in a whistle-blower lawsuit against Warner-Lambert describes how Proworx, a company owned by the ad giant Omnicom, offered to help article write journal articles about using Neurontin to treat pain. Proworx planned to recruit doctors to be the named authors of the articles, paying them a $1,500 fee. Omnicom declined to comment on the matter. Dr. Relman, the former editor of The New England Journal of Medicine, said there was no place in medical education for ad agencies. "We don't get anywhere in medicine without objective data," he said. "That's the coin of the realm.